Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Accumulated Expenses: 2020-2025

Historic Accumulated Expenses for Mereo BioPharma Group (MREO) over the last 2 years, with Sep 2025 value amounting to $4.1 million.

  • Mereo BioPharma Group's Accumulated Expenses rose 16.69% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year increase of 16.69%. This contributed to the annual value of $4.1 million for FY2024, which is 25.54% down from last year.
  • According to the latest figures from Q3 2025, Mereo BioPharma Group's Accumulated Expenses is $4.1 million, which was down 18.31% from $5.0 million recorded in Q2 2025.
  • In the past 5 years, Mereo BioPharma Group's Accumulated Expenses registered a high of $6.4 million during Q2 2022, and its lowest value of $2.5 million during Q1 2024.
  • Moreover, its 3-year median value for Accumulated Expenses was $3.9 million (2024), whereas its average is $3.9 million.
  • Per our database at Business Quant, Mereo BioPharma Group's Accumulated Expenses surged by 75.29% in 2021 and then declined by 25.54% in 2024.
  • Mereo BioPharma Group's Accumulated Expenses (Quarterly) stood at $5.2 million in 2021, then rose by 5.40% to $5.4 million in 2022, then rose by 0.57% to $5.5 million in 2023, then declined by 25.54% to $4.1 million in 2024, then grew by 16.69% to $4.1 million in 2025.
  • Its Accumulated Expenses was $4.1 million in Q3 2025, compared to $5.0 million in Q2 2025 and $2.9 million in Q1 2025.